- Home
- NEOV vs INZY Comparison
NEOV vs INZY Comparison
Compare NEOV & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- INZY
- Stock Information
- Founded
- NEOV 2018
- INZY 2015
- Country
- NEOV United States
- INZY United States
- Employees
- NEOV N/A
- INZY N/A
- Industry
- NEOV Industrial Machinery/Components
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- INZY Health Care
- Exchange
- NEOV Nasdaq
- INZY Nasdaq
- Market Cap
- NEOV 72.2M
- INZY 256.3M
- IPO Year
- NEOV N/A
- INZY 2020
- Fundamental
- Price
- NEOV $3.36
- INZY $4.00
- Analyst Decision
- NEOV Strong Buy
- INZY Buy
- Analyst Count
- NEOV 1
- INZY 9
- Target Price
- NEOV $7.50
- INZY $15.22
- AVG Volume (30 Days)
- NEOV 143.3K
- INZY 1.0M
- Earning Date
- NEOV 05-09-2025
- INZY 08-05-2025
- Dividend Yield
- NEOV N/A
- INZY N/A
- EPS Growth
- NEOV N/A
- INZY N/A
- EPS
- NEOV N/A
- INZY N/A
- Revenue
- NEOV $4,255,136.00
- INZY N/A
- Revenue This Year
- NEOV $208.50
- INZY N/A
- Revenue Next Year
- NEOV $128.75
- INZY N/A
- P/E Ratio
- NEOV N/A
- INZY N/A
- Revenue Growth
- NEOV 52.64
- INZY N/A
- 52 Week Low
- NEOV $1.80
- INZY $0.72
- 52 Week High
- NEOV $6.11
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- NEOV 62.26
- INZY 82.36
- Support Level
- NEOV $2.96
- INZY $3.94
- Resistance Level
- NEOV $3.04
- INZY $3.97
- Average True Range (ATR)
- NEOV 0.24
- INZY 0.01
- MACD
- NEOV 0.04
- INZY -0.09
- Stochastic Oscillator
- NEOV 93.83
- INZY 66.67
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.